INTRODUCTION

Babies are to be born as healthy as possible and progress through childhood and adolescence with a minimum of disruption, difficulty and disability. However, this is not uniformly the case in the 52 countries of the WHO European Region (Fig. 1). A new report by WHO (1) concludes that even in Europe most low-income countries will not meet the Millennium Development Goals, agreed on in 2000 by 189 countries, if the trends from the 1990s continue. Data have shown that countries with high child mortality have not improved their situations and death rates have even worsened in some (2).

We reviewed mortality and morbidity data for the five central Asian republics (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan) and the three Caucasus countries (Armenia, Azerbaijan and Georgia). All eight countries are part of the former Soviet Union and as such underwent an abrupt change in the organization of their health systems and a concurrent decline in the population's health status (3), as measured by inter alia life expectancy, cardiovascular disease and sexually transmitted infections (4). Here, in addition to reviewing the health status of children under the age of five in these countries, we also look at innovative changes in how the WHO Regional Office for Europe is addressing these problems.

CHILD HEALTH IN CENTRAL ASIA AND THE CAUCASUS

Although under-5 mortality is declining in the European Region, the probability of dying before the age of five continues to be of particular concern in the central Asian republics (CAR), other countries of the Commonwealth of Independent States and some countries of southern Europe (5). According to WHO estimates (3), the under-5 mortality varies by a factor of 40 between the countries with the lowest and the highest mortality in Europe. Data from the eight countries in CAR and the Caucasus show that they have higher under-five and neonatal mortality than the European Region on average. The rates WHO estimated in Table 1 show that Tajikistan and Turkmenistan stand out with an extremely high estimated under-5 mortality of 118 and 102 deaths per 1000 live births, respectively, and neonatal mortality rates of 38 and 35 per 1000 live births, respectively. The latter are closely followed by Kazakhstan and Kyrgyzstan. Azerbaijan and Georgia lead the Caucasus with regards to neonatal mortality, both at 25 per 1000, and under-5 mortality at 91 and 45 per 1000 live births, respectively. The latter are closely followed by Kazakhstan and Kyrgyzstan. Azerbaijan and Georgia lead the Caucasus with regards to neonatal mortality, both at 25 per 1000, and under-5 mortality at 91 and 45 per 1000 live births. The rates far exceed the European average of 11/1000. These figures clearly demonstrate the need for urgent interventions that improve child survival as well as child health and development (6, 7).

A REGIONAL STRATEGY FOR PRIORITISING CHILD HEALTH

Inequity in health needs to be reduced, but prioritising among several key areas is difficult and may often be resource demanding. Reaching the Millennium Development Goal for child survival will require the delivery of sustainable interventions and strategies to a high proportion of children and mothers (8, 9). Increased vaccination coverage (10), access to antenatal care (11) and environmental improvements (12) are some of the main needed interventions; however, local ownership including
selecting the interventions and strategies and adapting them to social, economic and cultural contexts can be both complicated and time consuming. To assist member states, the WHO Regional Office for Europe has recently developed a regional strategy on child and adolescent health (13) that focuses on seven priority areas within child and adolescent health (Table 2). The strategy was developed in collaboration with member states, and was presented and approved at the WHO Regional Committee’s fifty-fifth session in September 2005. Because of large cultural, social, economic and demographic differences in the Region, the strategy is to be seen as a guiding set of tools, and not a detailed blueprint, to help countries to prioritise and implement actions to improve child and adolescent health.

A LIFECYCLE APPROACH AT WHO

The regional strategy is based on an integrated approach developed by the Family and Community Health unit of the WHO Regional Office for Europe. It is clear that each stage of development involves determinants of health, biological risk and life events that will interact with each other. This interrelation will last throughout life and will even continue to future generations. Therefore, family and community health should be seen as an integrated task that deals with child and adolescent health in a circular, holistic way to ensure the health of the individual throughout the life course.

To ensure the continuity and avoid overlap, WHO/Europe has applied the lifecycle approach in the organization of its programmes and to the new regional strategy (Fig. 2). The idea of family and community health as a circular and holistic process is far from new and can be described by the lifecycle approach, which illustrates the main environmental and socio-cultural challenges for each stage of childhood and adolescence (14). Despite the benefits of integrated and horizontal efforts, few organizations employ this approach. The WHO lifecycle approach addresses key aspects of child and adolescent health, reproductive health, maternal health and gender mainstreaming in an integrated section, called family and community health, to achieve a more favourable outcome through collaboration and co-ordination. Two of the priority areas in the new strategy relate to specific stages in the life-course, namely maternal and newborn health, and adolescent health. Maternal and neonatal health will of course have an impact on the future well being of the developing child. Similarly, adolescent health and development will lay the foundations for health in later life and contribute to the health status of the next generation. The remaining five priority areas for WHO act as cross-cutting themes, influencing health and development at all stages of the lifecycle.

CO-OPERATION AND LINKED PROGRAMMES

The first sign of integrating approaches within child and adolescent health was the development of a Global Strategy on the Integrated Management of Childhood Illness (15). The programme integrates basic care for the most common childhood illnesses, preventive measures and family and community practices. Additionally, reproductive health has been linked to family and community health, and on 17 May 2004, WHO approved a global reproductive health strategy to “accelerate progress towards the attainment of international development goals and targets”. Grounded in the Millennium Development Goals, the WHO strategy focuses on meeting the three goals specifically
related to reproductive health: improving maternal health, reducing child mortality and combating HIV/AIDS, malaria and other infectious diseases. The targets set in these goals are to reduce 1990 levels by three-quarters by 2015 (16). The strategy further clarifies why reproductive health is unique as compared to other fields of health and why it needs to be an integrated part of family and community health. It states, “Reproductive health extends before and beyond the years of reproduction, and is closely associated with socio-cultural factors, gender roles and the respect and protection of human rights …”.

The Making Pregnancy Safer programme, launched in 2000, co-operates closely with the reproductive health programme and the programme on child and adolescent health and development at WHO/Europe. However, to improve the health situation it is not sufficient to just integrate the programmes at WHO. The health systems in low-income countries need to be developed to improve linkages between the aforementioned programmes of work. In effect, all aspects of maternal and child health should be interlinked within the context of policy and health systems support, appropriate case management, good family and community practices and the implementation of the United Nations Convention on the Rights of the Child.

CONCLUSION

Despite improvement in child health in Europe, we have found great inequity in child survival and health. Eight countries of the former Soviet Union have shown greater numbers of under-5 and neonatal mortality than the rest of Europe. In order to reach the Millennium Development Goals, immediate improvements are needed and therefore WHO/Europe has developed a regional strategy to support the countries in prioritising and decision-making. The new lifecycle approach at WHO illustrates that the health of the child and adolescent is intimately linked and shows that prevention and health promotion in one generation will benefit the health, well-being and productivity of the next generation. Furthermore, the lifecycle approach can help programmes identify where they have linkages with each other, whether they are targeting, partially or fully, the same group, and motivate for further horizontal collaboration. Eventually, co-ordinating and co-operating programmes and interventions will likely result in long-term improvements in child and adolescent health and development and thus be beneficial to economic growth and sustained improvements in public health.

REFERENCES


Table 2. The priority areas for Child and Adolescent Health and Development

<table>
<thead>
<tr>
<th>WHO’s seven priorities for Child and Adolescent Health and Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Maternal and neonatal health</td>
</tr>
<tr>
<td>2. Nutrition</td>
</tr>
<tr>
<td>3. Communicable diseases</td>
</tr>
<tr>
<td>4. Physical environment</td>
</tr>
<tr>
<td>5. Adolescent health</td>
</tr>
<tr>
<td>6. Injuries and violence</td>
</tr>
<tr>
<td>7. The physical environment</td>
</tr>
</tbody>
</table>

THE WORLD HEALTH ORGANIZATION ANNOUNCES NEW STANDARDS FOR REGISTRATION OF ALL HUMAN MEDICAL RESEARCH

Brussels/Geneva - The World Health Organization (WHO) is urging research institutions and companies to register all medical studies that test treatments on human beings, including the earliest studies, whether they involve patients or healthy volunteers. As part of the International Clinical Trials Registry Platform, a major initiative aimed at standardizing the way information on medical studies is made available to the public through a process called registration, WHO is also recommending that 20 key details be disclosed at the time studies are begun.

The initiative seeks to respond to growing public demands for transparency regarding all studies applying interventions to human participants, known as clinical trials. Before making the recommendations announced today, the Registry Platform initiative consulted with all concerned stakeholders, including representatives from the pharmaceutical, biotechnology and device industries, patient and consumer groups, governments, medical journal editors, ethics committees, and academia over a period of nearly two years.

“Registration of all clinical trials and full disclosure of key information at the time of registration are fundamental to ensuring transparency in medical research and fulfilling ethical responsibilities to patients and study participants,” said Dr Timothy Evans, Assistant Director-General of the World Health Organization.

Although registration is voluntary, there is a groundswell of policies aimed at spurring registration of all clinical trials. In July 2005, for example, the International Committee of Medical Journal Editors, a group representing 11 prestigious medical journals, instituted a policy whereby a scientific paper on clinical trial results cannot be published unless the trial had been recorded in a publicly-accessible registry at its outset.

Some groups have raised concerns that these new requirements could jeopardize academic or commercial competitive advantage if they apply to preliminary trials of new interventions. Similar concerns have been voiced about the requirement to disclose certain items—such as the scientific title of the study, the name of the treatment being tested and the outcomes expected from the study—at the time of registration.

“Our aim is to make clinical research transparent and enhance public trust in science, but we are engaged in a fair and open process with all stakeholders. We look forward to continued dialogue about trial registration and results reporting as we move forward with the Registry Platform,” said Dr Ida Sim, Associate Director for Medical Informatics at the University of California, San Francisco and coordinator of the Registry Platform initiative.

The planned Registry Platform will not be a register itself, but rather will provide a set of standards for all registers. It has not only standardized what must be reported to register a trial but is creating a global trial identification system that will confer a unique reference number on every qualified trial.

Currently, there are several hundred registers of clinical trials around the world but little coordination among them. The Registry Platform seeks to bring participating registers together in a global network to provide a single point of access to the information stored in them.

Later this year, the WHO Registry Platform will launch a web-based search portal where scientists, patients, doctors, donors and anyone else who is interested can search among participating registers for clinical trials taking place or completed throughout the world.

For further information please contact: Judith Mandelbaum-Schmid, Communications Officer, WHO, Geneva, tel: +41 22 791 2967, mobile: +41 79 254 6835, email: schmidj@who.int. And see frequently asked questions at: www.who.int/ictrp/fag/en/print.html. All press releases, fact sheets and other WHO media material may be found at www.who.int.

News Release WHO/25
19 May 2006